Recently, the biopharmaceutical industry has seen multiple developments: Quan Zhen Tong has released the “Quan Diagnosis 5.0” clinical AI intelligent partner; The approved protection rate of the Kanglewei trivalent HPV vaccine has been raised to 78%; Leica AI pathology quality control software received FDA certification, and Mayinglong’s three recombinant collagen wound repair products received Class II certification; CSPC’s monkeypox mRNA vaccine received FDA clinical approval; The first drug for acute altitude disease prevention was approved for market launch. 

---

1. Quan Zhen Tong and doctors jointly build exclusive clinical intelligence partners

. On August 10, domestic clinical AI solution provider Quan Zhen Tong held a new product launch event, iterating and releasing its core product line “Quan Zhen 5.0” and the multilingual international version of Clinmate after five monthsThis marks a key advancement in the application of medical AI in clinical scenarios, making it one of the few pioneering companies in the industry to realize the implementation of a “doctor-co-created clinical intelligence partner.”

The core upgrade of Full Diagnosis 5.0 addresses the real pain points in clinical scenarios, with distinct technical advantages and product positioning features:

• First, in terms of functionality, the product’s developed super intelligent can be deeply embedded in the entire diagnostic and treatment workflow, from initial consultation and treatment plan formulation to postoperative follow-up. At the same time, the service boundaries are extended to clinical teaching and research support scenarios, innovatively enabling advance medical record quality control nodes and built-in medical insurance compliance rules. Combined with optional privatization deployment plans, this not only meets medical institutions’ core data security demands but also effectively reduces the cost of digital transformation, fully meeting the compliance requirements of both domestic public and private healthcare systems;
• Second, in terms of model innovation, Full Diagnosis 5.0 builds an open clinical knowledge and skills base, breaking the traditional “one-way output” model of medical AI, supporting clinicians to independently accumulate exclusive diagnostic and treatment experience and customize personalized AI work partners, truly realizing the leap from “tool assistance” to “collaborative partner” positioning in medical AI.

The simultaneously launched international version of Clinmate has already taken the lead in multilingual adaptation, and will further promote localized debugging according to different regional healthcare system rules and explore integration with global healthcare systems.

---

2. Kangleweiser trivalent HPV vaccine approved for market

On August 12, Kangleweiser (Kunming) Biotechnology Co., Ltd.’s independently developed recombinant trivalent human papillomavirus (HPV) vaccine officially received the “Drug Registration Certificate” issued by the National Medical Products Administration.

As the core technological achievement in China’s HPV vaccine pipeline layout, the newly approved trivalent HPV vaccine innovatively incorporates HPV58, which has a rapidly increasing proportion of infections in the domestic population, based on the traditional bivalent vaccines covering HPV16 and 18, which are highly pathogenic subtypes. Clinical data have confirmed that it can increase the effective protection against female cervical cancer from 70% of traditional bivalent vaccines to 78%.It precisely fills the current gap in precise protection against high-incidence domestic subtypes of HPV vaccines, balancing effective prevention and public accessibility.

The production base in the Yunnan-Central New Area supporting this vaccine is designed to have an annual capacity of 10 million doses, fully building a full-chain large-scale production system for recombinant protein vaccines in accordance with GMP standards, with stable large-scale mass production and supply capability, fully meeting the vaccination needs of lower-tier domestic markets. Currently, the company is fully advancing preparations for commercial batch production, with official launch and sales expected to begin in April 2027, further enriching the domestic HPV vaccine market supply matrix and providing more cost-effective options for female cervical cancer prevention and control.

---

3. Leica Biosystems Accelerates Cancer Diagnosis

with Multiple FDA Certifications for Digital Pathology On August 11, Danaher’s core pathology subsidiary Leica Biosystems officially announced that several of its core digital pathology products have received FDA 510(k) marketing authorization in the United States. This approval further consolidates its technological leadership in the global interconnected clinical digital pathology track, injecting core momentum into the standardized upgrade of processes in the oncology precision diagnostics sector.

Among the approved matrices, the most notable in the industry is the world’s first independent AI-assisted pathology quality control software, Aperio iQC DX, which can automatically identify six types of high-frequency scan artifacts—including slide folds, contamination, and focal shift throughout the entire pathology slide scanning process—without the need for additional manual pre-calibration, enabling real-time quality control judgment. Publicly available real-world clinical validation data show that this AI software detects pathological artifacts 24% higher than senior organizational technicians, directly reducing manual review time by about 69%, fundamentally reducing the need for ineffective rescans, and greatly improving the overall circulation efficiency and result certainty of cancer pathology diagnosis.

Two clinical scanning hardware models adapted to different laboratory scenarios were also approved: the Aperio GT 450 DX for high-throughput head pathology labs adds a dedicated manual scanning module for complex sections, meeting the high-precision scanning needs of difficult and rare tumors; The Aperio GT 180 DX, aimed at medium-throughput medical institutions, focuses on building full-link interconnected digital pathology workflows, enabling full-process data integration from slicing to pathology reading.

To date, Leica Biosystems’ digital pathology product matrix can provide technical support for nearly 2 million early cancer screening and diagnostic tests worldwide per week. This approval further consolidates its industry-leading position in promoting the standardization and interconnection of global digital pathology.

---

4. National Medical Products Administration approves the launch of the innovative TCM drug Pediatric Digestive Granules
On August 11, the National Medical Products Administration officially approved the launch of Jichuan Pharmaceutical Group Co., Ltd.’s Class 1.1 innovative TCM drug, Pediatric Digestive Granules, which falls under the “Special Provisions on the Registration Administration of Traditional Chinese Medicine” After its release, it is the first innovative TCM drug in China primarily focused on TCM syndromes.

According to the approved public information, the approved effects of Xiao’er Tongbian Granules are clearly stated as strengthening the spleen, promoting qi circulation, and relieving constipation. Its indications precisely match those of pediatric constipation and TCM syndrome differentiation for people with food accumulation syndrome. It can specifically improve core clinical symptoms such as dry stools and difficulty defecating, providing clinicians and families with new treatment options better suited to the child’s physiological characteristics. Further refined the drug treatment matrix for pediatric constipation diseases.

---

5. Zhuhai Maidefa PHA Medical Device Certification, Opening a New Chapter in Clinical Applications Zhuhai

Maide Chemical Technology Co., Ltd.’s core product, ‘Disposable Sterile Tissue Closure Clip,’ has officially received the Class II medical device registration certificate from the National Medical Products Administration. It is the first domestic medical device to be approved for market use of polyhydroxyalk ester (PHA), marking a key leap for microbial synthetic biomaterial PHA from laboratory research and development to large-scale clinical application.

As a new generation biomedical material synthesized by microorganisms, PHA offers three core technological advantages: fully degradable in vivo with no residue, excellent biocompatibility with no tissue irritation, and precise control of mechanical properties through strain modification and synthesis processes. PHA can perfectly match the tensile tension requirements of tissue closure and postoperative metabolic requirements in surgery, making it ideal for general surgery, Minimally invasive surgical scenarios such as obstetrics and gynecology have broad clinical application prospects.

---

6. The “Three Musketeers” of Wound Repair Make Their Appearance: Mayinglong’s Medical Recombinant Collagen Products Fully Approved

On August 11, Mayinglong Pharmaceutical’s Wuhan Pony Pony Pentium Medical Technology Co., Ltd., as the registrant, officially announced three core wound repair products independently developed by the Group’s Health Research Institute—Medical Recombinant Collagen Repair Gel Liquid dressings, and wound repair patches. Recently, they simultaneously obtained the national Class II medical device registration certificate, marking the official implementation of Mayinglong’s core layout in the wound repair sector, making it one of the few pharmaceutical companies in China to achieve full dosage form coverage of the recombinant collagen wound repair pipeline.

The three approved products all use self-developed recombinant collagen as their core raw material. Leveraging Mayinglong’s decades of formulation development experience in the skin field, they achieve precise complementarity in formulations: gel types are suitable for small wound repair, liquid dressings are suitable for large-area wound wet compress care, and wound repair patches are suitable for closed wound protection scenariosIt can cover all kinds of superficial non-chronic wound repair needs across all scenarios. The raw materials and formulas have been verified through multiple toxicology and irritation tests, ensuring safety and non-irritation, suitable for all types of adult skin types, and can synergize with Mayinglong’s already launched Babao Recombinant Collagen series skincare products, building a full-chain skin health restoration ecosystem from wound medical repair to skin foundation stabilization and care.

The full approval of all three products not only further enriches Mayinglong’s product matrix in the skin health field, but also marks a core milestone in the brand’s upgrade from the mass-market efficacy skincare track to the professional medical-grade wound care track. Going forward, relying on the group’s R&D, channels, and brand accumulation, the company will continue to expand the commercialization pace of its medical-grade skincare pipeline.

---

7. Weishijia “Weishijia” Obtains Class III Medical Device Registration
Certificate OnJuly 28, Shenzhen Weishijia’s core product, the “Weishijia” night-wearable orthokeratology lenses (OK lenses), officially received the Class III medical device registration certificate from the National Medical Products Administration, marking the addition of a new player with core technological competitiveness to the domestic OK lens sector.

The newly approved Weishijia OK lenses have outstanding technical advantages in core performance: the product uses internationally clinically proven Boston XO2 high-oxygen permeability lens material, with an oxygen permeability coefficient of 141, which is industry-leading level. While ensuring nighttime wear safety, it can temporarily correct myopia for people with specific prescriptions.

Currently, Weiershi has completed multiple rounds of strategic financing, focusing on the optometry medical device sector. In addition to the approved Class III certification products, the company has already secured multiple pipelines under development and dozens of core technology patents. Supporting financing arrangements are progressing in an orderly manner. Going forward, it will further build a service system covering clinical and channel ends, with this product as the core, continuously improving its full-cycle optometry solution business matrix.

---

8. CSPC Group’s SYS6037 Injection Clinical Trial Approved

by FDA On August 10, CSPC Group disclosed progress in the development of two core pipelines:

• The first is the monkeypox mRNA vaccine SYS6037 injection, jointly developed with the Institute of Microbiology, Chinese Academy of Sciences, which has officially received FDA clinical trial approval in the United States, allowing clinical research to be conducted domestically. This vaccine is a candidate product encoding multiple antigens with a single mRNA strand specifically developed to meet the needs of monkeypox virus infection prevention. Compared to traditional orthopox virus vaccines and other multi-component mRNA vaccine routes, its technical architecture is simple and efficient. It greatly simplifies the quality control process in large-scale production, reduces supply chain complexity and overall production costs, and effectively improves the quality controllability of the entire vaccine chain and accessibility in global public health scenarios. It meets the urgent global demand for public health prevention and control of monkeypox.
• The second is CSPC Pharmaceutical Group’s independently developed first mRNA-LNP technology platform empowered by the CD19/BCMA dual-target CAR-T cell therapy product, which has officially launched Phase I clinical trials. The advancement of this pipeline further complements the company’s pipeline layout in the intersection of cell therapy and mRNA technology.

These two core pipelines have successively achieved critical breakthroughs, fully validating CSPC Group’s core technological advantages and mature R&D capabilities in mRNA technology independent R&D, industry-academia-research collaboration, and innovative cell therapy product development, while also building a core barrier for long-term competition in global infectious disease prevention and control and hematologic cancer treatment.

---

9. China’s first acute altitude disease prevention drug, “Acetazolamide Sustained-Release Capsules,” approved for market

On August 10, the country’s first acute altitude disease prevention drug developed under the leadership of Professor Gesang Luobu was officially approved by the National Medical Products Administration and successfully approved for market launch. This marks the completion of the key replacements in the domestic plateau medicine prevention and treatment drug system.

The drug is led by Professor Gesang Luobu, Vice President of Tibet Autonomous Region People’s Hospital and Director of the Tibet Plateau Medical Research Institute. The Phase III clinical trial was designed by his team, providing key evidence-based support for developing plateau disease prevention strategies suitable for Chinese and Asian populations. The related research findings were published in the flagship international high-altitude medicine journal “Plateau Medicine and Biology.”

Acetazolamide is a carbonic anhydrase inhibitor that effectively corrects respiratory alkalosis caused by high-altitude hypoxia by inhibiting carbonic anhydrase activity and promoting renal excretion of bicarbonate. Pingyuan participants in the Phase III clinical trial were enrolled at the cooperating Aerospace Center Hospital, and the plateau trial was organized and implemented in Tibet. The results showed that compared to the placebo group, the incidence of acute altitude sickness was significantly reduced in the medication group, with moderate to severe acute altitude sickness rates decreasing by 14.6%.

The approval and marketing of this product not only completely ends the previous awkward situation in China where there were no approved drugs for specific high-altitude disease prevention and clinical control could only rely on off-label extended drugs, but also, through the implementation of plateau-specific innovative drugs, it further consolidates Tibet’s core advantages in plateau medical research both domestically and globally, helping to deepen the influence of regional plateau medical research at the international level.

---

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.